Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection or Disease or with Concurrent Organ Dysfunction: A Phase 2 Open Label Study.

Saved in:
Bibliographic Details
Title: Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection or Disease or with Concurrent Organ Dysfunction: A Phase 2 Open Label Study.
Authors: Cheng MP; Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.; Division of Medical Microbiology, Department of Laboratory Medicine, McGill University Health Centre, Montreal, Quebec, Canada.; McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montreal, Quebec, Canada., Gonzalez-Bocco IH; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Arbonna-Haddad E; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA., Aleissa M; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia., Chen K; Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA., Zhou E; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Beluch K; Thomas Jefferson University, Philadelphia, PA, USA., Cho A; University of the Pacific, Arthur A. Dugoni School of Dentistry, San Francisco, CA, USA., Burchett S; Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA., Moulton E; Division of Infectious Diseases, Texas Children's Hospital, Houston, TX, USA., Desjardins M; Divisions of Infectious Diseases and Medical Microbiology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Koo S; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Letourneau AR; Harvard Medical School, Boston, MA, USA.; Divisions of Infectious Diseases and Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA., Hammond SP; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Divisions of Infectious Diseases and Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA., Ritz J; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Soiffer R; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Issa NC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kim HT; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Sherman AC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Source: Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada [J Assoc Med Microbiol Infect Dis Can] 2025 Jan 20; Vol. 10 (1), pp. 6-14. Date of Electronic Publication: 2025 Jan 20 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: University of Toronto Press Country of Publication: Canada NLM ID: 101763536 Publication Model: eCollection Cited Medium: Internet ISSN: 2371-0888 (Electronic) Linking ISSN: 23710888 NLM ISO Abbreviation: J Assoc Med Microbiol Infect Dis Can Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2371-0888
DOI:10.3138/jammi-2024-0016